Tezepelumab + Tezepelumab
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Eosinophilic Esophagitis
Conditions
Eosinophilic Esophagitis
Trial Timeline
Nov 10, 2022 → Mar 23, 2027
NCT ID
NCT05583227About Tezepelumab + Tezepelumab
Tezepelumab + Tezepelumab is a phase 3 stage product being developed by AstraZeneca for Eosinophilic Esophagitis. The current trial status is active. This product is registered under clinical trial identifier NCT05583227. Target conditions include Eosinophilic Esophagitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05583227 | Phase 3 | Active |
Competing Products
20 competing products in Eosinophilic Esophagitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KHK4563 + KHK4563 + KHK4563 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| benralizumab + benralizumab + Placebo | Kyowa Kirin | Phase 2 | 52 |
| SHR-1703 + SHR-1703 Placebo | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| NS-229 + Placebo | Nippon Shinyaku | Phase 2 | 52 |
| Esomeprazole + Budesonide | AstraZeneca | Phase 2/3 | 65 |
| Benralizumab | AstraZeneca | Approved | 85 |
| Cohort | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Matching placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab Prefilled Syringe | AstraZeneca | Approved | 85 |
| benralizumab | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| Tezepelumab + Placebo | AstraZeneca | Phase 2 | 52 |
| Benralizumab + Placebo | AstraZeneca | Phase 2/3 | 65 |
| inhaled/swallowed budesonide + viscous/swallowed budesonide | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + 129 Xenon | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |